From: Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study
P < 0.0001 HR 1.98
N = 134
OS Median months [95 % CI]
Risk 0
29
13.2 [9.6 – NR]
Risk 1
50
9.9 [6.7 – 11.8]
Risk 2
34
3.5 [2.7– 6.5]
Risk 3
13
2.4 [1.1 – 6.17]
Missinga
8